4Q Loss: $1.6 billion (earnings were $411 million 4Q25) ...

Revenues up 7% in the quarter despite €801 million loss.

AbbVie has submitted applications for a new indication for upadacitinib (RINVOQ) for the treatment of patients living with ...

Braveheart Bio is naming Marc Evanchik Chief Scientific Officer (CSO) and appointing Brittany de Temple Senior Vice President ...

ADARx Pharmaceuticals has named Donald Fong, MD, its new Chief Medical Officer (CMO). He served in the same post at BioCryst Pharmaceuticals.

In 2026, some of the key industry trends essential to company success and maintaining stability include long-lasting ...

“The global API manufacturing market is going through some major changes these days,” says Sean O’Brien, COO, Abzena. He ...

Charles River Laboratories will close its cell therapy contract development and manufacturing site in Hanover, Md., ...

Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...

Thermo Fisher Scientific will close a manufacturing facility in Franklin, Massachusetts, and eliminate up to 80 positions.

Driven by the growing prevalence of chronic diseases, the need for convenient and cost-effective drug delivery solutions, and ...

Sales growth was driven by both US Operations and International Operations. The volume growth of the global branded GLP-1 ...